➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Dow
Medtronic
Harvard Business School
AstraZeneca

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Galunisertib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Galunisertib?

Galunisertib is an investigational drug.

There have been 12 clinical trials for Galunisertib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Adenocarcinoma. The leading clinical trial sponsors are Eli Lilly and Company, Universitaire Ziekenhuizen Leuven, and Bristol-Myers Squibb.

There are seventy-four US patents protecting this investigational drug and eight hundred and fifteen international patents.

Recent Clinical Trials for Galunisertib
TitleSponsorPhase
Umbrella Biomarker-Guided Therapy in NPCSun Yat-sen UniversityPhase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2

See all Galunisertib clinical trials

Clinical Trial Summary for Galunisertib

Top disease conditions for Galunisertib
Top clinical trial sponsors for Galunisertib

See all Galunisertib clinical trials

US Patents for Galunisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galunisertib   Get Started Free Determination of TGF-.beta. pathway activity using unique combination of target genes KONINKLIJKE PHILIPS N.V. (Eindhoven, NL)   Get Started Free
Galunisertib   Get Started Free Compositions comprising bacterial strains 4D Pharma Research Limited (GB)   Get Started Free
Galunisertib   Get Started Free Compositions comprising bacterial strains 4D Pharma Research Limited (Aberdeen, GB)   Get Started Free
Galunisertib   Get Started Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Get Started Free
Galunisertib   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Galunisertib   Get Started Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Get Started Free
Galunisertib   Get Started Free Chemokine receptor modulators and uses thereof FLX Bio, Inc. (South San Francisco, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galunisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Galunisertib Australia AU2015334840 2034-10-24   Get Started Free
Galunisertib Brazil BR112017007965 2034-10-24   Get Started Free
Galunisertib Canada CA2965442 2034-10-24   Get Started Free
Galunisertib China CN107077536 2034-10-24   Get Started Free
Galunisertib Denmark DK3210142 2034-10-24   Get Started Free
Galunisertib European Patent Office EP3210142 2034-10-24   Get Started Free
Galunisertib Japan JP2018503354 2034-10-24   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Baxter
AstraZeneca
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.